Gabriele Ricci Sells 25,088 Shares of Takeda Pharmaceutical (NYSE:TAK) Stock

Key Points

• Insider sale: Gabriele Ricci sold 25,088 Takeda shares at an average price of $17.10, valued at approximately $429,005. The sale covered tax withholding obligations, reducing Ricci’s holdings by 12.75% to 171,654 shares.
• Stock performance and results: Takeda shares recently traded at $17.42, down 0.3%, with a market capitalization of $55.82 billion. The company reported quarterly revenue of $6.90 billion and earnings per share of $0.56.
• Mixed analyst outlook: Research firms have issued conflicting views, with two Buy ratings, one Hold, and one Sell; the overall consensus rating is Hold. Institutional investors and hedge funds own 9.17% of the company.

Takeda Pharmaceutical Co. (NYSE:TAK - Get Free Report) insider Gabriele Ricci sold 25,088 shares of the company's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $429,004.80. Following the completion of the transaction, the insider owned 171,654 shares of the company's stock, valued at approximately $2,935,283.40. This represents a 12.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Down 0.3%

Takeda Pharmaceutical stock traded down $0.06 during midday trading on Wednesday, hitting $17.42. 2,004,364 shares of the stock were exchanged, compared to its average volume of 4,402,927. Takeda Pharmaceutical Co. has a 1 year low of $12.99 and a 1 year high of $18.90. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.14 and a quick ratio of 0.62. The firm has a market cap of $55.82 billion, a P/E ratio of 51.24 and a beta of -0.08. The company has a 50 day moving average price of $16.49 and a two-hundred day moving average price of $17.13.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.The company had revenue of $6.90 billion during the quarter. On average, sell-side analysts predict that Takeda Pharmaceutical Co. will post 3.01 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Takeda Pharmaceutical

Hedge funds have recently bought and sold shares of the company. Valeo Financial Advisors LLC bought a new stake in Takeda Pharmaceutical in the second quarter valued at about $163,000. GAMMA Investing LLC lifted its holdings in Takeda Pharmaceutical by 10.7% during the 2nd quarter. GAMMA Investing LLC now owns 13,837 shares of the company's stock worth $222,000 after buying an additional 1,338 shares during the last quarter. Versant Capital Management Inc grew its position in shares of Takeda Pharmaceutical by 10.8% in the 2nd quarter. Versant Capital Management Inc now owns 42,686 shares of the company's stock worth $684,000 after acquiring an additional 4,169 shares in the last quarter. Parallel Advisors LLC grew its position in shares of Takeda Pharmaceutical by 10.5% in the 1st quarter. Parallel Advisors LLC now owns 24,651 shares of the company's stock worth $457,000 after acquiring an additional 2,343 shares in the last quarter. Finally, Glenmede Trust Co. NA increased its holdings in shares of Takeda Pharmaceutical by 9.6% in the 1st quarter. Glenmede Trust Co. NA now owns 30,205 shares of the company's stock valued at $559,000 after acquiring an additional 2,640 shares during the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have issued reports on TAK. Wall Street Zen upgraded Takeda Pharmaceutical from a "hold" rating to a "buy" rating in a report on Saturday, July 18th. Zacks Research upgraded Takeda Pharmaceutical from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 4th. Finally, Weiss Ratings lowered shares of Takeda Pharmaceutical from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Thursday, July 30th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold".

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited NYSE: TAK is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda's main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source